Literature DB >> 18378716

Antiparasitic activities and toxicities of individual enantiomers of the 8-aminoquinoline 8-[(4-amino-1-methylbutyl)amino]-6-methoxy-4-methyl-5-[3,4-dichlorophenoxy]quinoline succinate.

N P Dhammika Nanayakkara1, Arba L Ager, Marilyn S Bartlett, Vanessa Yardley, Simon L Croft, Ikhlas A Khan, James D McChesney, Larry A Walker.   

Abstract

8-Aminoquinolines are an important class of antiparasitic agents, with broad utility and excellent efficacy, but also limitations due to hematological toxicities, primarily methemoglobinemia and hemolysis. One representative from this class, (+/-)-8-[(4-amino-1-methylbutyl)amino]-6-methoxy-4-methyl-5-[3,4-dichlorophenoxy]quinoline succinate (NPC1161C), proved extremely efficacious in animal models of malaria and pneumocystis pneumonia. This racemic mixture was separated into its component enantiomers by chemical and chromatographic means. The enantiomers were evaluated for antiparasitic activity in murine models of Plasmodium berghei, Pneumocystis carinii, and Leishmania donovani infection, as well as the propensity to elicit hematotoxicity in dogs. The (-)-enantiomer NPC1161B was found to be more active (by severalfold, depending on the dosing regimen) than the (+)-enantiomer NPC1161A in all of these murine models. In addition, the (-) enantiomer showed markedly reduced general toxicity in mice and reduced hematotoxicity in the dog model of methemoglobinemia. It is concluded that the configuration at the asymmetric center in the 8-amino side chain differentially affects efficacy and toxicity profiles and thus may be an important determinant of the "therapeutic window" for compounds in this class.

Entities:  

Mesh:

Substances:

Year:  2008        PMID: 18378716      PMCID: PMC2415774          DOI: 10.1128/AAC.00645-07

Source DB:  PubMed          Journal:  Antimicrob Agents Chemother        ISSN: 0066-4804            Impact factor:   5.191


  46 in total

1.  Studies in the quinoline series; the preparation of some 8-(omega-alkylaminoalkylamino)-quinolines.

Authors:  K N CAMPBELL; A H SOMMERS
Journal:  J Am Chem Soc       Date:  1946-08       Impact factor: 15.419

2.  Clindamycin/primaquine for treatment of Pneumocystis carinii pneumonia in AIDS.

Authors:  E Toma
Journal:  Eur J Clin Microbiol Infect Dis       Date:  1991-03       Impact factor: 3.267

3.  Clindamycin and primaquine as primary treatment for mild and moderately severe Pneumocystis carinii pneumonia in patients with AIDS.

Authors:  J R Black; J Feinberg; R L Murphy; R J Fass; J Carey; F R Sattler
Journal:  Eur J Clin Microbiol Infect Dis       Date:  1991-03       Impact factor: 3.267

4.  In vitro effects of primaquine and primaquine metabolites on exoerythrocytic stages of Plasmodium berghei.

Authors:  M D Bates; S R Meshnick; C I Sigler; P Leland; M R Hollingdale
Journal:  Am J Trop Med Hyg       Date:  1990-06       Impact factor: 2.345

5.  Clindamycin with primaquine for Pneumocystis carinii pneumonia.

Authors:  E Toma; S Fournier; M Poisson; R Morisset; D Phaneuf; C Vega
Journal:  Lancet       Date:  1989-05-13       Impact factor: 79.321

6.  8-Aminoquinolines from Walter Reed Army Institute for Research for treatment and prophylaxis of Pneumocystis pneumonia in rat models.

Authors:  M S Bartlett; S F Queener; R R Tidwell; W K Milhous; J D Berman; W Y Ellis; J W Smith
Journal:  Antimicrob Agents Chemother       Date:  1991-02       Impact factor: 5.191

7.  Activity of clindamycin with primaquine against Pneumocystis carinii in vitro and in vivo.

Authors:  S F Queener; M S Bartlett; J D Richardson; M M Durkin; M A Jay; J W Smith
Journal:  Antimicrob Agents Chemother       Date:  1988-06       Impact factor: 5.191

8.  Efficacy of intermittent dosage of 8-aminoquinolines for therapy or prophylaxis of Pneumocystis pneumonia in rats.

Authors:  S F Queener; R A Dean; M S Bartlett; W K Milhous; J D Berman; W Y Ellis; J W Smith
Journal:  J Infect Dis       Date:  1992-04       Impact factor: 5.226

9.  Clindamycin/primaquine therapy and secondary prophylaxis against Pneumocystis carinii pneumonia in patients with AIDS.

Authors:  R Kay; R E DuBois
Journal:  South Med J       Date:  1990-04       Impact factor: 0.954

10.  Susceptibility of glucose-6-phosphate dehydrogenase deficient red cells to primaquine enantiomers and two putative metabolites--I. Effect on reduced glutathione, methemoglobin content and release of hemoglobin.

Authors:  S Agarwal; U R Gupta; R C Gupta; N Anand; S S Agarwal
Journal:  Biochem Pharmacol       Date:  1988-12-15       Impact factor: 5.858

View more
  26 in total

Review 1.  Malaria medicines: a glass half full?

Authors:  Timothy N C Wells; Rob Hooft van Huijsduijnen; Wesley C Van Voorhis
Journal:  Nat Rev Drug Discov       Date:  2015-05-22       Impact factor: 84.694

2.  Pharmacokinetics and pharmacodynamics of (+)-primaquine and (-)-primaquine enantiomers in rhesus macaques (Macaca mulatta).

Authors:  David Saunders; Pattaraporn Vanachayangkul; Rawiwan Imerbsin; Phisit Khemawoot; Raveewan Siripokasupkul; Babu L Tekwani; Aruna Sampath; N P Dhammika Nanayakkara; Colin Ohrt; Charlotte Lanteri; Montip Gettyacamin; Paktiya Teja-Isavadharm; Larry Walker
Journal:  Antimicrob Agents Chemother       Date:  2014-09-29       Impact factor: 5.191

3.  Tafenoquine: A Step toward Malaria Elimination.

Authors:  Kuan-Yi Lu; Emily R Derbyshire
Journal:  Biochemistry       Date:  2020-02-24       Impact factor: 3.162

4.  The 8-aminoquinoline analogue sitamaquine causes oxidative stress in Leishmania donovani promastigotes by targeting succinate dehydrogenase.

Authors:  Luis Carvalho; Juan Román Luque-Ortega; Carmen López-Martín; Santiago Castanys; Luis Rivas; Francisco Gamarro
Journal:  Antimicrob Agents Chemother       Date:  2011-06-13       Impact factor: 5.191

Review 5.  Killing the hypnozoite--drug discovery approaches to prevent relapse in Plasmodium vivax.

Authors:  Brice Campo; Omar Vandal; David L Wesche; Jeremy N Burrows
Journal:  Pathog Glob Health       Date:  2015-04-18       Impact factor: 2.894

6.  Tafenoquine, an antiplasmodial 8-aminoquinoline, targets leishmania respiratory complex III and induces apoptosis.

Authors:  Luis Carvalho; Juan Román Luque-Ortega; José Ignacio Manzano; Santiago Castanys; Luis Rivas; Francisco Gamarro
Journal:  Antimicrob Agents Chemother       Date:  2010-09-13       Impact factor: 5.191

7.  Antileishmanial and antitrypanosomal activities of the 8-aminoquinoline tafenoquine.

Authors:  Vanessa Yardley; Francisco Gamarro; Simon L Croft
Journal:  Antimicrob Agents Chemother       Date:  2010-09-13       Impact factor: 5.191

8.  Antineoplastic agents. 592. Highly effective cancer cell growth inhibitory structural modifications of dolastatin 10.

Authors:  George R Pettit; Fiona Hogan; Steven Toms
Journal:  J Nat Prod       Date:  2011-05-02       Impact factor: 4.050

Review 9.  Antimalarial drug discovery - approaches and progress towards new medicines.

Authors:  Erika L Flannery; Arnab K Chatterjee; Elizabeth A Winzeler
Journal:  Nat Rev Microbiol       Date:  2013-11-11       Impact factor: 60.633

10.  Peptidomimetic and organometallic derivatives of primaquine active against Leishmania infantum.

Authors:  Sílvia Vale-Costa; Nuno Vale; Joana Matos; Ana Tomás; Rui Moreira; Paula Gomes; Maria Salomé Gomes
Journal:  Antimicrob Agents Chemother       Date:  2012-08-27       Impact factor: 5.191

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.